Chugai/Debiopharm ink licence deal for Debio 1347

On 17th December 2012, Chugai Pharmaceutical and Debiopharm entered into a licensing agreement regarding Debio 1347 (FF284), an agent discovered by Chugai that is about to begin clinical development in oncology.

Under the agreement, Chugai will grant Debiopharm an exclusive licence to develop and commercialise FF284 in all countries worldwide, including Japan. Under the same agreement, Chugai will grant a non-exclusive licence to develop and commercialise a companion diagnostic for FF284. According to the terms of the licence, Debiopharm and Chugai will collaborate to conduct a Phase I dose-escalation study. In return for the licence, Chugai will receive an undisclosed up-front fee, and milestone and royalty payments from Debiopharm.

Agreement Information:
Agreement Status: New Date Announced: 8 Jan 2013
Date Last Reported: Duration:
Est Total Value: Investment To Date:
Agreement Type: Commercialisation
Generic / Brand Name: Debio 1347
Therapeutic Area: Antineoplastic and Immunomodulating Agents
Indication: Cancer
Techonology/Field: Diagnostics Drug development
This article is tagged to:
Sector: Medical Devices
Geography: Japan, Switzerland

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.